Youngjoo Kwon | Anticancer Drug Development | Innovative Research Award

Published on | Editorial Board by World Top Scientists

Innovative Research Award

Youngjoo Kwon
Institution Ewha Womans University
Country South Korea
Scopus ID 12446435600
Documents 181
Citations 5,351
h-index 36
Subject Area Anticancer Drug Development
Event World Top Scientist Awards
ORCID 0000-0001-6256-3042

Youngjoo Kwon – Ewha Womans University

Youngjoo Kwon is a Professor at Ewha Womans University whose research focuses on anticancer drug discovery, molecular pharmacology, and medicinal chemistry. His published work includes studies on topoisomerase inhibitors, heat shock proteins, and targeted cancer therapeutics. The following profile summarizes his academic background and research contributions based on publicly available scholarly records.[1]

Abstract

Professor Youngjoo Kwon has contributed extensively to anticancer drug development through studies involving DNA topoisomerase inhibition, molecular signaling pathways, and therapeutic target discovery. His research integrates medicinal chemistry with pharmacological evaluation to identify novel compounds for cancer treatment. Numerous publications demonstrate sustained activity in translational biomedical research.[2]

Keywords

Anticancer drug development, medicinal chemistry, molecular pharmacology, DNA topoisomerase inhibitors, HSP27, targeted therapy, drug discovery, cancer biology.

Introduction

Youngjoo Kwon has established a research program centered on the discovery and optimization of therapeutic compounds for cancer treatment. His studies combine medicinal chemistry, molecular biology, and pharmacological evaluation to identify drug candidates with improved efficacy and selectivity. Research outcomes have been reported in internationally recognized peer-reviewed journals, demonstrating sustained contributions to anticancer drug development.[5]

Research Profile

Since joining Ewha Womans University, Youngjoo Kwon has led research in oncology-focused medicinal chemistry with emphasis on novel small-molecule therapeutics. His ORCID profile lists numerous peer-reviewed publications covering anticancer compounds, fibrosis research, and molecular pharmacology while collaborating with international researchers across multidisciplinary projects.[3]

Research Contributions

His research has contributed to the understanding of DNA topoisomerase inhibition, heat shock protein biology, tumor progression, fibrosis, and molecular mechanisms associated with therapeutic resistance. These investigations support the development of innovative treatment strategies and provide valuable knowledge for future translational and pharmaceutical research.[2]

Publications

Youngjoo Kwon has authored and co-authored research articles published in internationally recognized journals including European Journal of Medicinal Chemistry, EMBO Reports, Journal of Medicinal Chemistry, and Pharmaceuticals. His publications primarily investigate topoisomerase inhibitors, HSP27-targeted therapies, and innovative anticancer compounds using molecular and pharmacological approaches.[4]

Research Impact

The research profile reflects continuous scientific productivity through numerous peer-reviewed publications, collaborations, and contributions to medicinal chemistry. His work has supported advancements in targeted anticancer therapies while serving as an important reference for researchers investigating novel therapeutic compounds and molecular drug targets.[3]

Award Suitability

Based on publicly available scholarly information, Youngjoo Kwon demonstrates an extensive record of research activity in medicinal chemistry and anticancer drug development. His sustained publication history, collaborative research, and scientific contributions align with the evaluation criteria commonly considered for international academic recognition programs.[1]

Conclusion

Youngjoo Kwon continues to contribute to cancer pharmacology through innovative medicinal chemistry research and multidisciplinary collaborations. His scientific publications and ongoing investigations highlight a consistent commitment to developing new therapeutic approaches for complex diseases while advancing knowledge in pharmaceutical sciences.

References

  1. Seo, S. H., Hwang, S. Y., Hwang, S., Han, S., Park, H., Lee, Y. S., Rho, S. B., & Kwon, Y. (2022). Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R. EMBO Reports, 23.
    https://doi.org/10.15252/embr.202152977
  2. Hwang, S. Y., Shrestha, A., Park, S., Bist, G., Kunwar, S., Kadayat, T. M., Jang, H., Seo, M., Sheen, N., Kim, S., Lee, E. S., & Kwon, Y. (2022). Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. European Journal of Medicinal Chemistry, 227, 113916.
    https://doi.org/10.1016/j.ejmech.2021.113916
  3. Jeon, K. H., Park, S., Jang, H. J., Hwang, S. Y., Shrestha, A., Lee, E. S., & Kwon, Y. (2021). AK-I-190, a new catalytic inhibitor of Topoisomerase II with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells. International Journal of Molecular Sciences, 22(20), 11246.
    https://doi.org/10.3390/ijms222011246
  4. Yim, J., Lim, H. H., & Kwon, Y. (2021). COVID-19 and pulmonary fibrosis: Therapeutics in clinical trials, repurposing, and potential development. Archives of Pharmacal Research, 44, 499-513.
    https://doi.org/10.1007/s12272-021-01331-9
  5. Kadayat, T. M., Park, S., Shrestha, A., Jo, H., Hwang, S. Y., Katila, P., Shrestha, R., Nepal, M. R., Noh, K., Kim, S. K., Lee, E. S., & Kwon, Y. (2019). Discovery and biological evaluations of halogenated 2,4-diphenyl indeno[1,2-b]pyridinol derivatives as potent Topoisomerase IIα-targeted chemotherapeutic agents for breast cancer. Journal of Medicinal Chemistry, 62(19), 9195-9213.
    https://doi.org/10.1021/acs.jmedchem.9b00970

Gildardo Rivera | Medicinal chemistry | Editorial Board Member

Published on | Editorial Board by World Top Scientists

Editorial Board Member

Gildardo Rivera
Instituto Politecnico Nacional

Gildardo Rivera
Affiliation Instituto Politecnico Nacional
Country Mexico
Scopus ID 24333214400
Documents 249
Citations 3,497
h-index 29
Subject Area Medicinal chemistry
Event World Top Scientist Awards
ORCID 0000-0001-9842-4167

Gildardo Rivera is a Mexican researcher recognized for his contributions to medicinal chemistry and interdisciplinary biomedical research. His academic career is associated with the Instituto Politecnico Nacional, where he has contributed to scientific development through extensive publications. His work primarily focuses on drug discovery, antimicrobial resistance, and computational chemistry approaches. Rivera’s scholarly output has achieved global visibility through citation impact and collaborative research networks [1].

Abstract

This article presents a structured academic overview of Gildardo Rivera’s contributions to medicinal chemistry and pharmaceutical sciences. It highlights his research output, citation metrics, and institutional affiliations within a global scientific context. The analysis integrates bibliometric indicators with qualitative evaluation of research domains. It aims to provide a comprehensive profile relevant for academic recognition and editorial positions.

Keywords

Medicinal chemistry, drug discovery, computational biology, antimicrobial resistance, pharmacological research, scientific publications, bibliometrics, molecular modeling, interdisciplinary science, pharmaceutical innovation.

Introduction

Medicinal chemistry plays a central role in modern healthcare innovation by enabling the development of targeted therapeutic agents. Researchers such as Gildardo Rivera contribute significantly through experimental and computational methodologies. His work integrates chemical synthesis, biological evaluation, and in silico modeling approaches. These interdisciplinary efforts align with global priorities in combating infectious and chronic diseases.

Research Profile

Rivera’s academic profile is characterized by sustained research productivity and international collaboration networks. His affiliation with Instituto Politecnico Nacional reflects strong institutional support for scientific advancement. The researcher has produced over two hundred indexed publications across high-impact journals. His work demonstrates a balance between theoretical modeling and applied biomedical research outcomes.

Research Contributions

The contributions of Rivera encompass antimicrobial drug discovery, anticancer studies, and computational screening methodologies. His studies frequently address global challenges such as antibiotic resistance and parasitic diseases. The integration of molecular docking and experimental validation strengthens the reliability of findings. These contributions have influenced ongoing research directions in pharmaceutical sciences.

Publications

Rivera’s publication record includes peer-reviewed articles focusing on drug design, pharmacological evaluation, and environmental health studies. His work spans journals such as Molecules, Medicinal Chemistry, and Environmental Science publications. The research demonstrates methodological diversity and interdisciplinary collaboration. These publications contribute to both theoretical frameworks and practical applications in medicinal chemistry.

Research Impact

The research impact of Rivera is reflected through citation metrics and academic influence across disciplines. With thousands of citations and a significant h-index, his work has achieved recognition in scientific communities. His publications support advancements in drug discovery and public health research. This impact underscores the relevance of his contributions in global biomedical science.

Award Suitability

Rivera’s academic achievements align with the criteria for international scientific awards and editorial roles. His consistent output and interdisciplinary research strengthen his professional standing. Recognition through global platforms highlights his contribution to advancing medicinal chemistry. Such credentials support his suitability for editorial board memberships and scientific honors.

Conclusion

The academic profile of Gildardo Rivera reflects a comprehensive contribution to medicinal chemistry and biomedical research. His work integrates experimental and computational techniques to address complex health challenges. The consistency of his scholarly output demonstrates sustained academic engagement. Overall, his profile supports recognition within global scientific and editorial communities.

References

  1. Blanco-Torres, E. C., Rivera, G., Delgado-Maldonado, T., Ortiz-Pérez, E., Paz-González, A. D., Martínez-Vázquez, A. V., et al. (2026). Food crops (Poaceae, Solanaceae, and Fabaceae) with anticancer nutraceutical prospects: A review of plant extracts. Molecules.
    https://doi.org/10.3390/molecules31122126
  2. Rivera, G., Navarrete-Carriola, D. V., De Angelis, L., Paz-González, A. D., Martínez-Vázquez, A. V., Ortiz-Pérez, E., et al. (2026). Biological evaluation of esters of 4-carboxylate-1,2,3-triazine as anti-Mycobacterium tuberculosis agents. Molecules.
    https://doi.org/10.3390/molecules31121993
  3. Paz-González, A. D., Rivera, G., Toledo-Bravo, K. N., Licea-Herrera, J. I., Lizarazo-Ortega, C., Bocanegra-García, V., et al. (2026). Antibiotic risk assessment in agricultural soil from Tamaulipas, Mexico. Journal of Environmental Science and Health, Part B.
    https://doi.org/10.1080/03601234.2026.2641965
  4. Blanco-Torres, E. C., Rivera, G., Delgado-Maldonado, T., Ortiz-Pérez, E., Paz-González, A. D., Martínez-Vázquez, A. V., et al. (2026). Anticancer potential of Cucurbitaceae, Brassicaceae, Liliaceae and Chenopodiaceae: A review of in vitro evidence. Molecules.
    https://doi.org/10.3390/molecules31111902
  5. Delgado-Maldonado, T., Moreno-Rodríguez, A., González-Morales, L. D., Flores-Villegas, A. L., Rodríguez-González, J., Rodríguez-Páez, L., et al. (2024). Design, synthesis, and evaluation of 1,3,4-oxadiazoles as anti-Trypanosoma cruzi agents. ChemMedChem.
    https://doi.org/10.1002/cmdc.202400241

Odinakachukwu Ehie | Health Professions | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Best Researcher Award

Odinakachukwu Ehie – University of California

Odinakachukwu Ehie
Affiliation University of California
Country United States
Scopus ID 57219775629
Documents 241
Citations 248
h-index 6
Subject Area Health Professions
Event World Top Scientist Awards

The Best Researcher Award recognizes the scholarly contributions of Odinakachukwu Ehie, a researcher affiliated with the University of California. His academic work reflects sustained engagement in medical research, particularly within health professions education and perioperative care. The award is associated with the World Top Scientist Awards platform, which acknowledges impactful scientific contributions globally [1]. This recognition highlights both research productivity and interdisciplinary engagement in contemporary healthcare challenges.

Abstract

This article presents an overview of Odinakachukwu Ehie’s research achievements and academic recognition. It contextualizes his contributions within healthcare research and medical education innovation. The award reflects measurable scholarly impact and consistent publication output. Emphasis is placed on interdisciplinary approaches and global health perspectives [2].

Keywords

Medical Education, Perioperative Care, Health Disparities, Clinical Research, Academic Recognition

Introduction

Modern healthcare research increasingly emphasizes equity, innovation, and interdisciplinary integration. Researchers such as Ehie contribute to these evolving priorities through applied clinical studies and educational frameworks. His work spans multiple domains including anesthesia, communication barriers, and systemic disparities. These efforts align with broader institutional goals of improving patient outcomes [3].

Research Profile

Ehie’s research profile includes over 241 indexed publications and measurable citation impact. His work is cataloged in Scopus under Author ID 57219775629. The researcher’s contributions demonstrate engagement with both theoretical and applied medical sciences. His profile reflects ongoing collaboration across institutions and disciplines [1].

Research Contributions

Key contributions include work on pulse oximetry disparities and medical education frameworks. His research addresses structural inequities in healthcare delivery systems. Additional studies examine communication dynamics in pediatric anesthesia and curriculum development. These contributions reflect a commitment to improving healthcare quality and accessibility [4].

Publications

Ehie has authored and co-authored several peer-reviewed publications in reputable journals. These works include studies in JAMA, BJA Education, and BMC Medical Education. His publications address both clinical practice and educational innovation. The research demonstrates methodological rigor and relevance to contemporary healthcare challenges [5].

Research Impact

The impact of Ehie’s research is reflected in citation metrics and interdisciplinary application. His work contributes to policy discussions and clinical best practices. The research also informs educational strategies within medical training programs. Such influence underscores the relevance of his academic contributions [3].

Award Suitability

The Best Researcher Award recognizes consistent academic output and societal impact. Ehie’s contributions align with criteria emphasizing innovation and relevance. His interdisciplinary approach strengthens the applicability of research findings. This makes him a suitable candidate for global recognition platforms [2].

Conclusion

Odinakachukwu Ehie’s academic profile reflects sustained contributions to healthcare research. His work demonstrates both depth and breadth across multiple disciplines. Recognition through the Best Researcher Award highlights his scholarly impact. Continued research activity is expected to further advance the field.

References

  1. Lipnick, M. S., Ehie, O., Igaga, E. N., & Bicker, P. (2025). Pulse oximetry and skin pigmentation: New guidance from the FDA. JAMA, 333(16), 1393–1395.
    https://pubmed.ncbi.nlm.nih.gov/40042945/
  2. Ehie, O., Wondimagegn, D., Whitehead, C. R., & Lee, A. (2025). Critical theory in medical education. BJA Education, 25(7), 281–288.
    https://pubmed.ncbi.nlm.nih.gov/40575593/
  3. Ehie, O., Wood, A., Barreto Chang, O., Langnas, E., Vu, T., Lilaonitkul, M., & Gropper, M. (2026). Perioperative outcomes and health disparities: Transforming healthcare. Journal of the National Medical Association.
    https://doi.org/10.1016/j.jnma.2026.01.003
  4. Jain, R., Lewis, L., Brooks, K., Shaahinfar, A., Stine, S., Marbin, J., & Ehie, O. (2026). Assessing the effectiveness of an antiracism clinical skills curriculum for medical students: A single institution mixed methods study. BMC Medical Education.
    https://doi.org/10.1186/s12909-026-08854-z
  5. Branche, K., Gallardo, P., Carreon, Y., & Ehie, O. (2026). Enhancing communication in pediatric anesthesia: The impact of language barriers on caregiver and provider interaction. Pediatric Anesthesia, 36(3), 271–280.
    https://doi.org/10.1002/pan.70102

Klaus Schmitz-Abe | Medicine and Dentistry | Best Researcher Award | 4538

Published on | Editorial Board by World Top Scientists

Best Researcher Award

Klaus Schmitz-Abe
Affiliation University of Miami
Country United States
Scopus ID 55566516000
Documents 2133
Citations 2284
h-index 26
Subject Area Medicine and Dentistry
Event World Top Scientist Awards
ORCID 0000-0002-7242-8861

Klaus Schmitz-Abe – University of Miami

Klaus Schmitz-Abe is a biomedical researcher affiliated with the University of Miami and recognized for his contributions to genomic medicine, rare disease research, computational biology, and clinical genetics. His academic activities integrate advanced sequencing technologies, bioinformatics methodologies, and translational research approaches that support the identification and interpretation of disease-causing genetic variants. Through collaborations with leading healthcare and research institutions, he has contributed to projects focused on improving diagnostic precision and expanding knowledge of inherited disorders. His research profile reflects a multidisciplinary approach that bridges computational science with clinical medicine, supporting innovation in precision healthcare and evidence-based patient management.[1]

Abstract

This article presents an academic overview of Klaus Schmitz-Abe in relation to the Best Researcher Award. His research activities encompass genomic medicine, human genetics, rare disease diagnostics, computational biology, and translational healthcare. Through collaborative investigations and publication of peer-reviewed studies, he has contributed to improving the understanding of genetic disorders and advancing modern diagnostic methodologies. His work demonstrates the integration of bioinformatics, sequencing technologies, and clinical interpretation frameworks that support precision medicine initiatives. The combination of scientific productivity, interdisciplinary collaboration, and translational relevance highlights a research profile suitable for international academic recognition.[2]

Keywords

Genomic Medicine, Human Genetics, Rare Diseases, Bioinformatics, Clinical Genomics, Precision Medicine, Immunology, Translational Research.

Introduction

The growing importance of genomic technologies has transformed the way researchers investigate inherited diseases and complex medical conditions. Scientists working in this field contribute significantly to improving diagnostic accuracy and expanding the understanding of disease mechanisms. Klaus Schmitz-Abe has participated in research efforts that combine computational methods with clinical investigation, creating opportunities for more efficient genetic diagnosis and personalized healthcare solutions. His scholarly work reflects the evolving role of genomics in contemporary medicine and biomedical research.[3]

Research Profile

Klaus Schmitz-Abe has held research and academic appointments associated with the University of Miami, Harvard Medical School, Boston Children’s Hospital, and several collaborative genomic research initiatives. His expertise includes next-generation sequencing, variant interpretation, copy number variation analysis, phenotype-driven diagnostics, and bioinformatics. These areas of specialization have enabled him to participate in multidisciplinary projects involving rare diseases, immune disorders, and developmental conditions. His professional activities demonstrate continuous engagement with clinical and translational research programs focused on improving patient outcomes through genomic science.[1]

Research Contributions

The scientific contributions of Klaus Schmitz-Abe include studies addressing genetic disorders, immunological diseases, autism spectrum conditions, and genomic diagnostic methodologies. His work frequently focuses on identifying clinically relevant genetic variants and improving analytical frameworks used in medical genetics. Several publications highlight the application of computational approaches and integrated genomic analyses that increase diagnostic yield and support precision medicine. These contributions have enhanced scientific understanding while also providing practical value for clinical decision-making and healthcare innovation.[4]

Publications

  • Unique Signatures of Highly Constrained Genes Across Publicly Available Genomic Databases (2025).
  • RELMβ Sets the Threshold for Microbiome-Dependent Oral Tolerance (2025).
  • DOCK8 Deficiency Due to a Deep Intronic Variant in Hyper-IgE Syndrome (2024).
  • Homozygous Deletions Implicate Non-Coding Epigenetic Marks in Autism Spectrum Disorder (2020).
  • Unique Bioinformatic Approach and Comprehensive Reanalysis Improve Diagnostic Yield of Clinical Exomes (2019).

These publications illustrate sustained engagement with genomics, immunology, and rare disease research. The studies collectively demonstrate an emphasis on clinically relevant discoveries, methodological innovation, and translational applications. Research findings reported in these works contribute to the advancement of genetic diagnostics and support broader scientific efforts aimed at understanding disease biology and improving patient care.[5]

Research Impact

Research impact can be assessed through scholarly productivity, citation influence, collaborative participation, and translational significance. The academic record associated with Klaus Schmitz-Abe demonstrates continued involvement in projects that address important challenges in genomic medicine and clinical genetics. His contributions have supported the development of diagnostic strategies and generated findings relevant to healthcare professionals, researchers, and patients. The combination of scientific output and practical relevance strengthens the overall significance of his research portfolio.[2]

Award Suitability

The Best Researcher Award recognizes excellence in scientific achievement, innovation, collaboration, and measurable academic contribution. Klaus Schmitz-Abe’s work aligns with these criteria through his multidisciplinary research activities and sustained publication record. His involvement in genomic medicine, rare disease investigation, and computational biology reflects a commitment to advancing scientific knowledge while supporting practical clinical applications. Such achievements provide a strong foundation for recognition within an international academic award framework.[3]

Conclusion

Klaus Schmitz-Abe has developed a research profile characterized by interdisciplinary collaboration, scientific productivity, and contributions to genomic medicine. His work supports advances in rare disease diagnosis, precision medicine, and computational genetics while maintaining strong relevance to modern healthcare challenges. Through peer-reviewed publications, collaborative research programs, and translational investigations, he has contributed to the ongoing evolution of biomedical science. These accomplishments collectively support his recognition within the Best Researcher Award category.[4]

References

  1. ORCID. Klaus E. Schmitz-Abe Profile.
    https://orcid.org/0000-0002-7242-8861
  2. Unique Signatures of Highly Constrained Genes Across Publicly Available Genomic Databases.
    https://doi.org/10.1016/j.gim.2025.101413
  3. RELMβ Sets the Threshold for Microbiome-Dependent Oral Tolerance.
    https://doi.org/10.1038/s41586-024-08440-7
  4. DOCK8 Deficiency Due to a Deep Intronic Variant in Two Kindreds with Hyper-IgE Syndrome.
    https://doi.org/10.1016/j.clim.2024.110384
  5. Unique Bioinformatic Approach and Comprehensive Reanalysis Improve Diagnostic Yield of Clinical Exomes.
    https://doi.org/10.1038/s41431-019-0401-x

Sara Franzi | Biology Transplantology | Women Researcher Award

Published on | Editorial Board by World Top Scientists

Dr. Sara Franzi | Biology Transplantology | Women Researcher Award

Researcher | Policlinico of Milan | Italy

Dr. Sara Franzi is a Researcher at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan, specializing in transplantation biology and biomedical research. She holds advanced academic training in life sciences, with a strong foundation in molecular and cellular biology. Her professional trajectory includes postdoctoral fellowships and research appointments at leading Italian IRCCS institutes, where she has contributed to multidisciplinary projects in thoracic surgery, lung transplantation, neuroimmunology, and neuromuscular diseases. Her work spans experimental and translational research, including studies on TGF-beta signaling in myopathies, genetic determinants of drug response in myasthenia gravis, and immune-mediated neurological disorders. She has demonstrated leadership in coordinating research initiatives and contributes to scientific dissemination as a medical writer and reviewer for peer-reviewed journals. Dr. Franzi’s research output includes publications in reputable journals, reflecting her commitment to advancing knowledge in transplantation and disease mechanisms. Her professional affiliations, editorial contributions, and continued engagement in high-impact research underscore her recognition within the scientific community.

Citation Metrics (Google Scholar)

392
300
200
100
0

392

11

10

Citations

Documents

h-index


Top 5 Featured Publications

 

Rabab Hassan Elshaikh Mahmoud | Hematology | Research Excellence Award

Published on | Editorial Board by World Top Scientists

Assist. Prof. Dr. Rabab Hassan Elshaikh Mahmoud | Hematology | Research Excellence Award

Assistant professor | A’ Sharqiyah University | Oman

Assist. Prof. Dr. Rabab Hassan Elshaikh Mahmoud is an Assistant Professor in Medical Laboratory Sciences at A’Sharqiyah University, specializing in hematology, immunohematology, and immunology, with extensive expertise bridging academic research and clinical laboratory practice. She holds advanced degrees in medical laboratory science with specialization in hematology and immunology, complemented by formal training in business administration, quality management, and laboratory safety. With nearly two decades of professional experience, she has served in academic teaching, graduation project supervision, laboratory leadership, quality coordination, and program review roles, contributing to curriculum development and accreditation activities. Her research focus spans hematologic disorders, transfusion medicine, immunological diagnostics, laboratory quality systems, and clinical pathology, with published work cited internationally and active involvement as a peer reviewer for scientific journals. Her professional standing is reinforced by international certifications, licensure from multiple health authorities, participation in global accreditation programs, and membership in recognized professional societies, reflecting sustained commitment to research excellence, quality advancement, and scientific integrity in laboratory medicine.

Citation Metrics (Google Scholar)

247
200
150
100
50
0

247

6

4

Citations

h-index

i10-index


Top 5 Featured Publications

 

Jeimylo De Castro| Medicine and Dentistry | Research Excellence Award

Published on | Editorial Board by World Top Scientists

Prof. Dr. Jeimylo De Castro| Medicine and Dentistry | Research Excellence Award

Medical Director | SMARTMD | Philippines

Prof. Dr Jeimylo de Castro is a clinician-researcher with a strong scholarly focus on musculoskeletal ultrasound, regenerative medicine, chronic pain, neuropathic pain, lifestyle medicine, and non-surgical interventions, supported by peer-reviewed publications, book chapters, editorial leadership, and consistent citation impact. Author Strengths: the author demonstrates translational research expertise, leadership in emerging therapeutic technologies, interdisciplinary integration of imaging and regenerative approaches, and active engagement as a reviewer and academic contributor, reflecting credibility and influence within specialized research communities. Areas of Improvement: expanding multi-center research collaborations, increasing publication volume in high-impact journals, and strengthening longitudinal outcome studies could further enhance visibility and citation reach. Future Potential: the author shows strong promise to lead innovation-driven research, mentor future investigators, and shape global practice standards through evidence-based scholarship and international academic engagement.

 

Citation Metrics (Google Scholar)

14
10
7
4
0

14

12

2

Citations

Documents

h-index

Kartik Bhatia | Medicine and Dentistry | Research Excellence Award

Published on | Editorial Board by World Top Scientists

Assoc. Prof. Dr. Kartik Bhatia | Medicine and Dentistry | Research Excellence Award 

Clinical Associate Professor | University of Sydney | Australia

Associate Professor Dr. Kartik Dev Bhatia is an interventional neuroradiologist at the Sydney Children’s Hospital Network with expertise in paediatric and adult neuroendovascular care, recognized for establishing comprehensive services in clot retrieval for stroke and intra-arterial therapy for retinoblastoma. He holds a PhD and advanced clinical qualifications including subspecialty recognition in interventional neuroradiology, fellowship of the Royal Australian and New Zealand College of Radiologists, and dual medical and surgical degrees, underpinning a strong academic and clinical foundation. His professional experience spans leadership of multidisciplinary cerebrovascular programs, major fellowships across leading Australian and international centres, and service as a staff specialist and consultant interventional neuroradiologist across multiple tertiary hospitals. Dr. Bhatia’s research focuses on paediatric neurointervention, stroke, vascular malformations, and innovative endovascular therapies, with influential publications in high-impact journals and contributions to key international registries. He has authored multiple book chapters and serves as a reviewer for prominent journals in neuroradiology, neurology, and stroke medicine, reflecting his standing in the academic community. His work has advanced understanding of paediatric cerebrovascular disease, liquid biopsy applications in vascular malformations, and endovascular treatment paradigms. A recipient of distinctions including a Research Excellence Award, he also contributes through editorial activities, scholarly mentorship, and active membership in multidisciplinary and professional bodies. Dr. Bhatia’s blend of clinical innovation, academic leadership, and sustained research impact positions him as an outstanding candidate for recognition.

Citation Metrics (Google Scholar)

1500
1000
500
0

1409
Citations

22
h-index

30
i10-index


View Google Scholar Profile

Top Publications

Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Published on | Editorial Board by World Top Scientists

Assoc. Prof. Dr. Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Associate Professor | Dima Jimma university | Ethiopia

Assoc. Prof. Dr. Feyera Gemeda Dima is a distinguished researcher and academic with extensive experience in Infectious Diseases, Medical Mycology, and Medicine. He has demonstrated excellence in teaching, research, and mentorship at both national and international levels, fostering the development of students and early-career researchers. His work emphasizes innovation in scientific research, editorial contributions, and leadership in grant assessment and curriculum development. He has contributed significantly to global collaborations and serves as a Chief Scientist and Global Assessor, reflecting his commitment to advancing scientific knowledge. His research focuses on improving understanding and management of infectious diseases, with the potential to influence public health strategies. Prof. Gemeda’s dedication to integrating innovative approaches and interdisciplinary perspectives underscores his capacity for impactful contributions in the field.

Profile:  Google Scholar

Featured Publications

1. T. Gizaw and F. G. Dima, “Assessment of problems and constraints associated with artificial insemination service in the two selected districts of Arsi zone,” Journal of Harmonized Research in Medical and Health Sciences, vol. 3, no. 1, pp. 14–37, 2016.

2. A. Edao, F. G. Dima, and F. B. Deressa, “Prevalence of bovine cysticercosis and status of human taeniasis in and around Asella town, Tiyoworeda, south east Ethiopia,” Glob J Med Res, vol. 16, pp. 18–26, 2016.

3. F. Gemeda, “Prevalence of bovine Trypanosomosis in and around Nekemte areas, east Wollega zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 05, p. 1, 2015.

4. D. T. Legesse and F. Gemeda, “Comparison of two parasitological tests and post mortem examination to detect prevalence of bovine fasciolosis at Ambo Town Municipal Abattoir, West Shewa Zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 8, pp. 1–5, 2015.

5. F. G. Dima and T. Fikedu, “Review on infectious bovine keratoconjunctivitis,” J Bacteriol Infect Dis, vol. 4, no. 4, pp. 1–6, 2021.

Dr. Gemeda’s work advances the understanding and control of infectious diseases, providing evidence-driven insights that strengthen public health systems and guide global disease management strategies.

Na Eun Lee | Extracellular Vesicles | Best Researcher Award

Published on | Editorial Board by World Top Scientists

Ms. Na Eun Lee | Extracellular Vesicles | Best Researcher Award

Senior Research Scientist | Sungkyunkwan University | South Korea

Ms. Na Eun Lee, Ph.D. Candidate at the Department of Health Sciences and Technology (SAIHST), Sungkyunkwan University, is an accomplished researcher specializing in regenerative medicine, stem cell biology, and translational health sciences. She holds a Master’s degree in Health Sciences and Technology from Sungkyunkwan University and a Bachelor’s degree in Applied Biochemistry from Konkuk University. Currently pursuing her doctoral studies, she integrates molecular and cellular approaches to advance extracellular vesicle-based therapeutics and skin rejuvenation technologies. Throughout her professional career, Ms. Lee has held senior scientific and leadership positions at prominent biomedical companies and research institutions, where she directed projects in cell therapy development, angiogenesis research, and clinical translation. Her scholarly contributions include publications in high-impact journals such as Cytotherapy, Biochemical and Biophysical Research Communications, and the International Journal of Molecular Sciences, highlighting innovations in mesenchymal stromal cell biology and nano-encapsulation delivery systems. Renowned for her expertise in extracellular vesicle analysis, molecular diagnostics, and regenerative research, Ms. Lee’s work bridges fundamental science and clinical application. She has been recognized for her research excellence and leadership in biomedical innovation, contributing actively to the advancement of stem cell-based therapeutic strategies and representing a distinguished example of scientific dedication and translational impact in the field of health sciences and technology.

Profiles: ORCID

Featured Publications

1 S. J. Yang, J. K. Son, S. J. Hong, N. E. Lee, D. Y. Shin, S. H. Park, S. B. An, Y. C. Sung, J. B. Park, and H. M. Yang, et al., “Ectopic vascularized bone formation by human umbilical cord-derived mesenchymal stromal cells expressing bone morphogenetic factor-2 and endothelial cells,” Biochemical and Biophysical Research Communications.

2 N. E. Lee, S. J. Kim, S. J. Yang, S. Y. Joo, H. Park, K. W. Lee, H. M. Yang, and J. B. Park, “Comparative characterization of mesenchymal stromal cells from multiple abdominal adipose tissues and enrichment of angiogenic ability via CD146 molecule,” Cytotherapy.

3 H. M. Yang, H. J. Choi, D. P. Hong, S. Y. Joo, N. E. Lee, J. Y. Song, Y. L. Choi, J. Lee, D. Choi, B. Kim, et al., “The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex,” Experimental and Molecular Pathology.